Does Aripiprazole Reduce Anxiety?
Yes, aripiprazole can reduce anxiety symptoms, with evidence supporting its use both as monotherapy and as augmentation therapy in anxiety disorders and major depressive disorder with comorbid anxiety. 1, 2, 3, 4
Evidence for Anxiolytic Effects
The most recent comprehensive review (2026) examining adjunctive pharmacotherapy for major depressive disorder with anxiety symptoms found that aripiprazole has been shown to improve both depression and anxiety symptoms in patients with MDD and anxiety symptoms, though the evidence is primarily derived from short-term exploratory post hoc analyses 1. This positions aripiprazole among the atypical antipsychotics with demonstrated benefit in this population.
Clinical Trial Data
Multiple clinical studies support aripiprazole's anxiolytic properties:
Open-label augmentation studies demonstrated that aripiprazole significantly reduced anxiety symptoms in patients with generalized anxiety disorder and panic disorder who remained symptomatic despite adequate first-line treatment. In one 8-week study, 59% of patients showed marked improvement (CGI-I ratings of 1-2) with doses of 15-30 mg/day 3, 4.
Response rates were clinically meaningful, with some patients showing early response (weeks 1-5) that was sustained through 12 weeks of treatment 4.
The drug demonstrated efficacy across multiple anxiety presentations including panic disorder, generalized anxiety disorder, social anxiety, and post-traumatic stress disorder 4.
Mechanism and Preclinical Support
Aripiprazole's unique mechanism as a partial agonist at dopamine D2 receptors (rather than a silent antagonist like other antipsychotics) may contribute to its anti-aversive properties. Animal models demonstrated anxiolytic- and panicolytic-like effects at doses as low as 0.1-1 mg/kg, with attenuation of escape responses and reduced freezing behavior in fear conditioning paradigms 5.
Special Considerations for Your Patient Context
Renal Impairment (eGFR ≈46 mL/min)
Aripiprazole does not require dose adjustment in renal impairment. Unlike bupropion, which is extensively metabolized to active metabolites that are renally excreted and can accumulate in renal impairment 6, aripiprazole is primarily hepatically metabolized. This makes aripiprazole a safer choice in this clinical scenario.
Bupropion Co-Administration
Your patient is already on bupropion, which itself has emerging evidence for anxiety reduction in MDD with comorbid anxiety. A 2025 systematic review found that bupropion provides clinically relevant improvement in anxiety symptoms in adults with MDD, with generally comparable efficacy to SSRIs in most presentations 7. However, bupropion requires dose reduction and/or decreased dosing frequency in patients with renal impairment (GFR <90 mL/min) due to accumulation of renally-cleared metabolites 6.
The combination of bupropion and aripiprazole may provide complementary mechanisms for addressing both depressive and anxiety symptoms, though close monitoring for adverse reactions is warranted given the renal impairment.
Tolerability Profile
Common side effects in anxiety studies included sedation, restlessness, and chest discomfort, with discontinuation rates around 13% 3. However, aripiprazole generally demonstrates a favorable tolerability profile compared to other atypical antipsychotics, particularly regarding metabolic effects.
Clinical Bottom Line
For a patient with moderate renal impairment on bupropion, aripiprazole is an appropriate option for anxiety reduction with no required dose adjustment for renal function. The evidence supports its use as augmentation therapy, with typical effective doses ranging from 15-30 mg/day. Monitor closely for tolerability, particularly sedation and akathisia, and ensure bupropion dosing is appropriately adjusted for the patient's renal function to minimize accumulation risk.